Identification of Primary Natural Killer Cell Modulators by Chemical Library Screening with a Luciferase-Based Functional Assay by Hayek, Simon et al.
HAL Id: hal-02324386
https://hal.archives-ouvertes.fr/hal-02324386
Submitted on 23 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Identification of Primary Natural Killer Cell Modulators
by Chemical Library Screening with a Luciferase-Based
Functional Assay
Simon Hayek, Nassima Bekaddour, Laurie Besson, Rodolphe Alves de Sousa,
Nicolas Pietrancosta, Sébastien Viel, Nikaïa Smith, Yves Jacob, Sébastien
Nisole, Rupasri Mandal, et al.
To cite this version:
Simon Hayek, Nassima Bekaddour, Laurie Besson, Rodolphe Alves de Sousa, Nicolas Pietrancosta, et
al.. Identification of Primary Natural Killer Cell Modulators by Chemical Library Screening with
a Luciferase-Based Functional Assay. Slas Discovery, SAGE Publishing, 2018, 24 (1), pp.25-37.
￿10.1177/2472555218797078￿. ￿hal-02324386￿
Identification of Primary Natural Killer Cell Modulators by Chemical 
Library Screening with a Luciferase Based Functional Assay 
Simon Hayek1, Nassima Bekaddour1, Laurie Besson2,3, Rodolphe Alves de Sousa1, Nicolas 
Pietrancosta1, Sébastien Viel2,3, Nikaia Smith1, Yves Jacob4, Sébastien Nisole5, Rupasri 
Mandal6, David S. Wishart6, Thierry Walzer2, Jean-Philippe Herbeuval1, Pierre-Olivier 
Vidalain1 
1 Chimie & Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Université 
Paris Descartes, CNRS UMR8601, Paris, France.  
2 Centre International de recherche en Infectiologie, CIRI, Inserm, U1111, Université Claude 
Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, University of Lyon, 
Lyon, France.  
3 Laboratoire d’Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-
Bénite, France. 
4 UMR 3569, CNRS, Unité de Génétique Moléculaire des Virus à ARN, Institut Pasteur, 
Université Paris Diderot, Paris, France. 
5 Institut de Recherche en Infectiologie de Montpellier CNRS UMR 9004, Université de 
Montpellier, Montpellier, France 
6 Departments of Biological Sciences and Computing Science, University of Alberta, 
Edmonton, Alberta T6G 2E9, Canada. 
 
* Corresponding author:  
Tel: +33 (0)1 45 68 87 73 Fax: +33 (0)1 40 61 3167 
e-mail: pierre-olivier.vidalain@parisdescartes.fr 
 
Keywords: Natural Killer cells, luciferase, screening, dextromethorphan, diphenhydramine  
 Abstract (max 200 words) 
Natural Killer (NK) cells are essential players of the innate immune response that 
secrete cytolytic factors and cytokines such as IFN-g when contacting virus-infected or tumor 
cells. They represent prime targets in immunotherapy as defects in NK cell functions are 
hallmarks of many pathological conditions such as cancer and chronic infections. The 
functional screening of chemical libraries or biologics would greatly help identify new 
modulators of NK cell activity, but commonly used methods such as flow cytometry are not 
easily scalable to high-throughput settings. Here we describe an efficient assay to measure the 
natural cytotoxicity of primary NK cells where the bioluminescent enzyme NanoLuc is 
constitutively expressed in the cytoplasm of target cells, and is released in co-culture 
supernatants when lysis occurs. We fully characterized this assay using either purified NK 
cells or total PBMCs, including some patient sample, as effector cells. A pilot screen was also 
performed on a library of 782 metabolites, xenobiotics and common drugs, which identified 
dextrometorphan and diphenhydramine as novel NK cell inhibitors. Finally, this assay was 
further improved by developing a dual reporter cell line to simultaneously measure NK cell 
cytotoxicity and IFN-g secretion in a single well, extending the potential of this system. 
  
 Introduction 
NK (Natural Killer) cells are essential players of the immune response against viruses 
and tumor cells1. As group 1 innate cytotoxic lymphoid cells, they are characterized by a 
potent cytotoxicity and the ability to secrete IFN-g when activated. In human, they represent 
5-20% of peripheral blood mononuclear cells (PBMCs). NK cells express a set of membrane 
receptors allowing them to discriminate normal cells from abnormal, virus-infected or tumor 
cells. Tumorigenesis and viral infection are indeed often accompanied by the downregulation 
of NK cell inhibitory ligands and/or the upregulation of activator ligands at the cell surface, 
allowing target cell detection by NK cells. Once activated, NK cells release the pore forming 
protein perforin2, and pro-apoptotic factors including granzymes and death ligands (FasL, 
TRAIL, etc). Besides, secreted IFN-g contributes to the activation of other effector cells and 
the induction of an appropriate immune response. As such, NK cells are prime targets in 
immunotherapy and defects in their activation are hallmarks of pathological conditions 
including cancers, genetic disorders and viral chronic infections. Functional assays measuring 
NK cell cytotoxicity in vitro or ex vivo, are therefore essential to evaluate the potential impact 
of small molecules, antibodies or proteins on this immune cell population. 
The reference method to measure the cytotoxic activity of NK cells ex vivo is based on 
the release of chromium 51 (51Cr) by target cells pre-loaded with this radioactive isotope3. 
When target cells are co-incubated with NK cells, the permeabilization of their membrane is 
accompanied by the release of 51Cr in culture supernatant, which reflects the cytolytic activity 
of NK cells. This method has been widely used for decades, but is progressively abandoned 
because of the risks and regulatory constraints associated with the manipulation of radioactive 
elements. A more recent and popular method is based on the use of multi-color flow 
cytometry to quantify the lysis of target cells in co-cultures4. Fluorescent dyes or specific 
membrane markers are used to discriminate NK cells from target cells at the time of analysis, 
 while the fraction of dead target cells is calculated using viability dies. Alternatively, NK cell 
cytotoxicity can be indirectly quantified by surface immunostaining of the degranulation 
marker CD107a (LAMP1), which is correlated with NK cell-mediated lysis5. Although 
widely used, all methods based on flow cytometry require some expensive equipment, trained 
personal, and are time-consuming at both the acquisition and analysis steps. For these 
reasons, they are not well adapted to large-scale screening projects, and alternative strategies 
have been developed to measure NK cells activation in high-throughput settings.  
Established strategies include the quantification of secreted IFN-γ by ELISA in co-
culture supernatants, which is tractable for high-throughput screenings (HTS)6, 7. However, 
IFN-γ secretion is not always correlated with the cytotoxic activity, a limitation that adds to 
the significant cost and multi-step protocol inherent to ELISA. Other described tests involve 
the co-culture of PBMCs or NK cells with adherent target cells8. After incubation, effector 
cells and dead target cells are washed out, and the number of living target cells still attached 
to culture wells is quantified by different methods. Alternatively, the number of adherent 
target cells in co-cultures, without the need of washing-out NK cells, can be determined by 
electrical impedance measurements9. However, such assays are limited to adherent target 
cells, and rely on the quantification of surviving cells in culture wells rather than a direct 
quantification of cell lysis. Finally, non-radioactive alternatives to 51Cr have been developed 
such as calcein, a fluorescent molecule, that can be loaded as a pro-form (Calcein-AM) in 
target cells10. However, calcein staining relies on endogenous cellular esterase for processing 
the pro-form of the dye and was criticized for its low signal-to-noise ratio. Europium was also 
used as a non-radioactive substitute to 51Cr, but never became popular due to some high 
background observed in many target cell lines11. Other cytotoxicity assays are based on the 
release of endogenous cytosolic enzymes such as lactate dehydrogenase12. This enzyme can 
be detected in culture supernatants with synthetic substrates that are converted into colored or 
 fluorescent products. The sensitivity of these methods has been a matter of debates, in 
particular in co-cultures because when dying, not only target cells but also effectors cells 
potentially release such endogenous enzymes in the medium. Therefore, there are still some 
unmet needs for a sensitive high-throughput assay to measure the cytotoxicity of NK cells. 
Along with the development of firefly luciferase as a reporter in biological systems, 
bioluminescent assays have been engineered to measure NK cell cytotoxicity. 
Decarboxylation of the luciferase substrate luciferin by firefly luciferase leads to light 
emission that can be quantified. Interestingly, this reaction requires ATP that is essentially 
present in living but not dead cells. Thus, target cells were engineered to express firefly 
luciferase, and co-cultured with NK cells. When luciferin is added to culture wells, it 
penetrates all cells in the co-culture but is only processed by luciferase-expressing target cells 
that are alive and produce ATP13. This method was shown to outperform the standard 51Cr 
cytotoxicity assay, but is dependent on intracellular ATP levels and signal-to-noise ratio can 
be low in common target cell lines such as K56214. In parallel, other research groups tried to 
develop cytotoxicity assays based on the release of firefly luciferase in culture supernatants 
when lysis occurs15, 16. However, this approach was hampered by the short half-life of firefly 
luciferase in culture medium at 37°C. Recently, the development of high performance 
luciferases derived from marine organisms has provided a new start to this approach17, 18. The 
best example is NanoLuc, a synthetic luciferase of 19 kDa developed by Promega from a 
luminescent enzyme of the sea shrimp Oplophorus gracilirostris19. This enzyme uses 
furimazine as a substrate, of which decarboxylation is ATP independent. NanoLuc is >150 
times brighter than firefly luciferase and more importantly, is stable for days in culture 
medium. We took advantage of this new generation of luciferase to develop a high-throughput 
functional assay to measure the natural cytotoxicity of primary NK cells (Fig. 1). Two clonal 
cells lines expressing high levels of NanoLuc in their cytoplasm, called K562-NL and 
 twINNE, were engineered, and NanoLuc release in culture supernatant was determined in co-
cultures with purified effector cells including primary NK cells, total PBMCs from healthy 
donors, treated or not with cytokines or immunomodulatory compounds, and PBMCs from a 
perforin deficient patient. We also established that NanoLuc release by target cells is robust 
enough to screen chemical libraries in high-throughput settings and to identify modulators of 
NK cell activity. Finally, we further improved this assay by developing the dual reporter cell 
line twINNE where a firefly luciferase reporter gene is used to monitor interferon signaling in 
target cells while in parallel, NanoLuc release is reporting their lysis. 
 
Material and Methods 
Cells and culture conditions 
Cells were cultured at 37°C and 5% CO2 in RPMI-1640 medium (Sigma-Aldrich; 
R8758) containing 10% fetal calf serum (FCS). Human K562 cells were kindly provided by 
Dr. T. Walzer (CIRI, Lyon). The reporter cell line STING-37, corresponding to HEK-293 
cells stably transfected with the ISRE-luciferase reporter gene, was previously described 20. 
Blood from healthy blood bank donors was obtained from “Etablissement Français du Sang” 
(Convention # 07/CABANEL/106; Paris; France). Human peripheral blood mononuclear cells 
(PBMC) were isolated by density centrifugation with Lymphoprep medium (StemCell 
Technologies) from total blood or leucocytes concentrates obtained when plateletpheresis is 
performed. NK cells were purified from PBMC using the NK cell isolation kit from Miltenyi. 
Recovered NK cells were pure at >94% as assessed by their CD3-/CD56+ phenotype. A 
patient with a confirmed homozygous missense mutation in PRF1 was included in this study. 
A blood sample was obtained upon informed consent. 
 
Cytokines, small compounds and reagents 
 IL-2, IL-15, and TGF-b were obtained from Peprotec. R848 was obtained from 
Sigma-Aldrich, Torin2 was from Tocris, and Rapamycin was from Calbiochem. Luciferase 
induction in twINNE cells was determined using the Bright-Glo (Promega) or Britelite plus 
reagents (PerkinElmer), according to the manufacturer’s recommendations. Nanoluc 
expression was quantified in culture supernatants as previously described19. Cellular viability 
was determined by quantification of ATP in culture wells using the CellTiter-Glo assay 
(Promega). Bioluminescence was measured for 0.1 s with a luminometer (EnSpire; 
PerkinElmer). Tergitol NP9 was from Sigma-Aldrich. 
 
Establishing K562-NanoLuc and twINNE cell lines 
The NanoLuc gene was introduced in target cells by transduction with the pLVX-Puro 
lentiviral vector (Clontech). First, the NanoLuc sequence was cloned in the pLVX-Puro 
vector using the Gateway cloning system (Thermo Fisher Scientific). Briefly, the pLVX-Puro 
plasmid was made compatible with the Gateway system by inserting the Gateway cassette C1 
at the SmaI site to generate the new destination vector called pLVX-Puro-GW. A pDONR207 
plasmid containing the coding sequence for the NanoLuc enzyme (Promega) was kindly 
provided by Dr. Y. Jacob (Institut Pasteur, Paris). The NanoLuc sequence was transferred by 
in vitro LR recombination from pDONR207 to pLVX-Puro-GW vector following 
manufacturer’s recommendations to obtain pLVX-Puro-NanoLuc. This vector was used to 
produce lentiviral particles by co-transfection with packaging plasmids pVSV-G and pGag-
Pol (kindly provided by Dr. S. Nisole; IRIM; Montpellier) into HEK-293T cells. Culture 
supernatants containing lentiviral particles were collected two days later and stored at -80°C. 
K562 and STING-37 cells were transduced with the lentiviral vector expressing 
NanoLuc, and puromycin at 1 µg/ml was applied for 4 weeks to enrich the cellular pool for 
transduced cells. Using a cell sorter, 576 and 63 cells were cloned from the transduced 
 populations of K562 and STING-37 cells, respectively. After 4 weeks, culture wells were 
tested for the expression of NanoLuc to identify best growing clones expressing high levels of 
the enzyme. Top candidates were amplified for establishing the K562-NL and the twINNE 
cell lines, which respectively correspond to K562 and STING-37 clones expressing high 
levels of NanoLuc. 
 
Cell cytotoxicity assay. 
PBMC from healthy donors were incubated overnight in the absence or presence of 
compounds to be tested. Unless specified otherwise, PBMC were plated in 96-well round-
bottom plates at a concentration of 400,000 cells/well in a final volume of 100 µL. After 16 h, 
16,000 K562-NanoLuc or 100,000 twINNE cells were added to cultures wells (100 µL of a 
cell suspension at 160,000 cells/ml or 1.10+6 cells/ml, respectively). Total volume in culture 
wells was 200 µL, and plates were centrifuged briefly for 2 min at 1,200 rpm. Unless 
specified otherwise, 20 µL of culture supernatants were collected after 4 h or 7 h of co-culture 
for K562-NL or twINNE, respectively, and NanoLuc activity was determined by adding 40 
µL of RPMI-1640 and 30 µL of NanoLuc reagent (as described in 19; Promega) in black, flat-
bottom, 96 ½-well plates. Bioluminescence was measured during 0.1 s with a luminometer 
(Enspire; PerkinElmer). 
To quantify the death of target cells by flow cytometry, K562-NL cells were labeled 
with the VDP450 dye at 1 µM in PBS (BD Biosciences). After 10 min of incubation at 37°C, 
cells were washed thoroughly in culture medium, en co-cultured with PBMCs as described 
above. After 4 h, cells were collected and dead cells were labeled using the LIVE/DEAD 
fixable green stain reagent from Invitrogen following manufacturer’s recommendations. Cells 
were analyzed by flow cytometry, and the percentage of dead K562-NL cells was determined 
by gating on the VDP450+ cells. 
  
Screening of the TMIC Human Metabolome Library. 
The TMIC Human Metabolome Library was obtained from The Metabolomics 
Innovation Center in Canada (TMIC; www.metabolomicscentre.ca). It is a comprehensive 
library of compounds representing a broad range of metabolites, xenobiotics and drugs 
commonly found in body tissues. Briefly, 5 mg of each compound was dissolved in 2 ml of 
either pure water or a 50% mix of water and DMSO to achieve a final stock concentration of 
2.5 mg/ml. Compounds were rearrayed in deep-well plates, and daughter plates were prepared 
by spotting 2 µL in round-bottom 96-well plates for screening. Culture wells were filled with 
PBMC at 400,000 cells/well in a final volume of 100 µL as described above, so that test 
compounds were at 50 µg/ml. For each screening plate, negative control wells were filled 
with culture medium alone, whereas positive control wells were filled with PBMC plus 2 µL 
of a 50% water:DMSO mixture. After 16 h, 16,000 K562-NanoLuc cells were added to all 
cultures wells (100 µL of a cell suspension at 160,000 cells/ml). NanoLuc activity in culture 
supernatants was determined after 4 h of co-culture as described above, and results were 
expressed as a percentage relative to positive control wells. The Z’ factor that reflects the 
robustness and quality of the assay was calculated from means (μ+ and μ-) and standard 
deviations (σ+ and σ-) of negative and positive controls such as Z' = 1-3*(σ+ + σ-)/(μ+ - μ-) 
as described by Zhang JH & al 21. Very good assays have Z’ factors that are close or superior 
to 0.5. The signal-to-background ratio (S/B ratio) corresponds to μ+/μ-, and the signal-to-
noise ratio (S/N ratio) to (μ+ - μ-)/σ- as previously defined 21. 
 
Results  
Development and assessment of the K562-NL reporter cell line 
 Myeloid leukemia cells K562 were transduced with a lentiviral vector to express 
NanoLuc, and cell clones were carefully screened to select those expressing this 
bioluminescent enzyme at high levels. The best cellular clone was amplified to establish the 
K562-NL reporter cell line. First, we tested if NanoLuc is released in culture supernatants 
when membrane permeabilization occurs. K562-NL cells were treated with 1% Tergitol as a 
detergent to lyse cells and culture supernatants were harvested at different time-points. Cell 
lysis was confirmed by standard light microscopy (data not shown). As presented in Fig. 2A, 
high levels of NanoLuc activity were detected in culture supernatants and were maximal after 
only 3 min. As expected, ATP in culture wells, which is a common biomarker of cellular 
metabolic activity and used to determine viability, was gradually degraded in the 0-30 min 
time-window showing that NanoLuc release is concomitant with cell death. 
Since our goal was to determine whether K562-NL cells can be used as target cells to 
measure the cytotoxic activity of NK cells in PBMCs, we verified that NanoLuc activity in 
culture supernatants is not impaired by the addition of a large number of PBMCs in the 
culture wells. Increasing numbers of K562-NL cells - ranging from 2,500 to 80,000 cells - 
were dispensed in culture wells of a 96-well plate and killed by freezing-and-thawing. Then, 
400,000 PBMCs were added or not to culture wells and after centrifugation, culture 
supernatants were immediately collected to quantify NanoLuc activity. As expected, the 
NanoLuc activity dramatically increased in culture supernatants when K562-NL cells were 
killed and more importantly, the signal was not affected by the addition of PBMCs to culture 
wells (Fig. 2B). We also verified that the NanoLuc signal in culture supernatants of killed 
K562-NL cells mixed with PBMCs was stable in time, without any significant loss over 24 h 
(data not shown). Altogether, this demonstrated that NanoLuc release in culture supernatants 
of K562-NL cells is suitable to monitor their lysis by NK cells. 
 
 Measuring NK cell cytotoxicity with K562-NL target cells  
A fixed number of K562-NL cells – herein referred as the target cells – were co-
cultured with PBMCs – the effector cells – at different effector/target (E/T) ratios ranging 
from 0.8 to 50. After 4 h of incubation, culture supernatants were harvested and tested for 
NanoLuc activity. Results were expressed as the percentage of NanoLuc released by K652-
NL cells permeabilized with 1% Tergitol. As shown in Fig. 3A, NanoLuc activity increased 
proportionally with E/T ratios. We also performed the same experiment quantifying the 
number of dead K562-NL cells in co-cultures by chemical staining (LIVE/DEAD reagent) 
and conventional flow cytometry analysis. NanoLuc accumulation in culture supernatants 
appeared to be more sensitive than flow cytometry, as the killing of K652-NL cells was 
detectable at lower E/T ratios (Fig. 3A). We also performed the same co-culture experiment at 
a 25/1 ratio and quantified NanoLuc in supernatants at different time-points (Fig. 3B). As 
expected, the signal continuously increased over 8 h of co-culture. After 24 h of co-culture, 
100% lysis was reached in these co-culture conditions (data not shown). However, 4 h were 
sufficient to obtain a strong signal that is statistically distinct from K562-NL cells alone. 
Finally, donor-to-donor variation was assessed by testing PBMCs from 13 different donors at 
an E/T ratio of 25/1, and measuring lysis of target cells after 4 h of co-culture (Fig. 3C). 
Altogether, this demonstrated the efficiency and robustness of this assay to detect the 
cytotoxic activity of PBMCs. 
The percentage of NK cells in PBMCs varies from 5 to 20%. We thus performed the 
same assay with NK cells purified from PBMCs. As expected, NanoLuc activity increased in 
culture supernatants of K562-NL cells when co-cultured with purified NK cells (Fig. 3D) and 
reached high levels at lower E/T ratios than previously reported with total PBMCs. 
Furthermore, we showed that when PBMCs were depleted of NK cells, NanoLuc did not 
accumulate anymore in co-culture supernatants (Fig. 3E). Reconstitution with purified NK 
 cells restored the cytotoxic activity of PBMCs and the accumulation of NanoLuc in culture 
supernatants. Altogether, this data demonstrated the key role of NK cells in the cytotoxicity of 
PBMCs towards K562-NL cells and the accumulation of NanoLuc in culture supernatants. 
 
Testing the effects of known modulators of NK cell cytotoxicity 
We then tested in this assay the effect of small compounds or cytokines that are known 
to modulate NK cell cytotoxicity, either directly or indirectly. First, PBMCs were stimulated 
with R848 (or resiquimod), a small agonist of TLR7 and TLR8. R848 mimics the 
immunostimulatory effects of single-stranded viral RNA molecules and stimulates NK cell 
cytotoxicity through the activation of antigen-presenting cells. PBMCs were pretreated 
overnight with R848, and K562-NL target cells were added. After 4 h of co-culture, NanoLuc 
activity in culture supernatants was measured. As shown in Fig. 4A, R848 increased NanoLuc 
levels in co-culture supernatants as a consequence of NK cell stimulation. Similar results were 
obtained when pretreating PBMCs with IL-15, a cytokine known to increase the cytotoxicity 
of NK cells (Fig. 4B)22. Alternatively, PBMCs were pretreated overnight with TGF-b, a 
cytokine known to inhibit NK cell functions23. As expected, NanoLuc accumulation in co-
culture supernatants was reduced (Fig. 4B). Similar results were obtained with Torin2, a 
potent inhibitor of the mTOR pathway that is essential to NK cell cytotoxicity (Fig. 4B)22. 
Altogether, these results demonstrated that our assay is suitable to screen small compounds or 
cytokines to identify new inhibitors or activators of NK cells. 
Familial histiolymphocytosis (FHL) is a severe inflammatory condition characterized 
by abnormally activated macrophages infiltrating multiple tissues, hepato-splenomegaly, non-
remitting high fever, cytopenia, hypertriglyceridemia and hyperferritinemia. It is caused by 
gene mutations that impair NK and CD8 T cell cytotoxic function. In this group of diseases, 
perforin (PRF1) deficiency is responsible for FHL type 2 (FHL2). Quick diagnosis of FHL 
 and potent treatment are essential to prevent fatal evolution. To determine if our assay could 
help in the diagnosis of such pathological condition, PBMCs from a perforin deficient patient 
were tested. Because of technical constraints, PBMCs from this patient and the matching 
healthy control were conserved for overnight at 4°C before the assay could be performed. 
This probably accounts for the low cytotoxic activity detected with control PBMCs even at a 
high E/T ratio. Nevertheless, results obtained clearly showed that PBMCs from the perforin 
deficient patient have completely lost their cytotoxic activity as assessed by the absence 
NanoLuc accumulation in culture supernatants (Fig. 4C). Therefore, this assay can be used to 
monitor ex vivo the cytotoxic activity of NK cells from patients while starting from a blood 
sample of only few milliliters and could be used as a screening test in the diagnosis of 
diseases caused by defects in lymphocyte cytotoxicity. 
 
Screening a chemical library of metabolites, xenobiotics and common drugs 
Our next objective was to test if our NanoLuc-based functional assay was suitable to 
rapidly screen hundreds of molecules using fresh PBMCs. To establish a proof of concept, we 
selected a chemical library from The Metabolomics Innovation Center (TMIC, Canada) that 
aggregates 782 metabolites, xenobiotics, and frequently used over-the-counter medications: 
the TMIC Human Metabolome Library. Our objective was to determine if some of these 
molecules might impact the function of NK cells, with potential consequences on the 
organism’s ability to fight against virus infections or tumors.  
PBMCs from two healthy donors were incubated overnight with compounds at 50 
µg/ml, and K562-NL target cells were added to evaluate the cytotoxic activity of NK cells. 
Each screening plate included either 4 (Donor #1) or 7 (Donor #2) positive and negative 
controls that corresponded to PBMCs + K562-NL cells or K562-NL cells alone, respectively. 
After 4 h of co-culture, NanoLuc activity was measured in culture supernatants. On average, 
 the signal-to-background (S/B) ratio, which corresponds to the mean value of positive 
controls (μ+) divided by the mean value of negative controls (μ-), was 8.6 for Donor #1, and 
19.2 for Donor #2. The signal-to-noise (S/N) ratio, which corresponds to the difference of μ+ 
minus μ- relative to the standard deviation of negative controls (σ-), was 22.2 for Donor #1, 
and 66.5 for Donor #2. The Z’ factor, which reflects the overall quality of the assay and is 
calculated with the formula 1-3*(σ+ + σ-)/(μ+ - μ-), was 0.49 for Donor #1 and 0.61 for 
Donor #2. Altogether, these statistical parameters qualify this assay for HTS21. In parallel, 
PBMCs were incubated in the same conditions with test compounds, and ATP levels in 
culture wells were determined to identify toxic molecules (Fig. 5A). 80 compounds reduced 
ATP levels by more than 25%, thus supporting some significant impact on cellular metabolic 
activity and viability. Of the remaining 702 compounds, 12 compounds were found to inhibit 
the lysis of target cells by >75% in the two screens, supporting the inhibition of NK cell 
cytotoxicity towards target cells (Fig. 5A). 
Interestingly, 6 of these compounds were previously reported to inhibit NK cells (Fig. 
5B), thus confirming the robustness of our screening pipeline24-29. We also identified 6 
compounds as new inhibitors, including 3 metabolites (7-dehydrocholesterol, oleanolic acid, 
and tryptamine), and 3 medications (dextrometorphan, diphenhydramine, brompheniramine). 
These compounds were retested in dose-response experiments using PBMCs from at least 
three healthy donors to estimate the half maximal inhibitory concentrations, which ranges 
from 10 to 126 µM (Fig. 5C). Dextrometorphan and diphenhydramine were particularly 
interesting because of the potent inhibition of target lysis, and a limited impact on the 
viability of PBMCs. 
 
Development of a dual reporter assay to measure both target cell lysis and IFN secretion 
 NK cell activation is associated to the production of type II interferon (IFN-g), which 
is released through vesicles and secretory pathways that are distinct from cytotoxic granules30. 
In order to further improve our screening assay, we developed new target cells for monitoring 
both the cytotoxic activity and the production of interferons by NK cells. We previously 
developed a HEK-293 cell line stably transfected with a firefly luciferase reporter gene 
controlled by Interferon-Stimulated Response Elements (ISRE) in its promoter (STING-37 
cell line)20. These reporter cells not only respond to type I IFNs but also to IFN-g, which 
efficiently induced the expression of firefly luciferase (Fig 6A), making them suitable to 
detect the secretion of this cytokine by activated NK cells. Thus, STING-37 cells were 
engineered to express NanoLuc, so that NK cell cytotoxicity can be concomitantly monitored 
in the same culture wells. Best clones were amplified and carefully selected to establish a 
reporter cell line that we called twINNE because of its dual reporter system based on firefly 
and NanoLuc luciferases. When these cells were co-cultured with PBMCs for 7 h at relatively 
low E/T ratios ranging from 0.5:1 to 4:1, NanoLuc expression in culture supernatants 
increased as a consequence of target cell lysis (Fig. 6B). In parallel, the cellular expression of 
firefly luciferase increased as the ISRE-luciferase reporter was induced in co-cultures (Fig. 
6B). When the same experiment was performed at higher E/T ratios, the expression of firefly 
luciferase did not increase (data not shown), probably because target cells were lysed before 
the induction of the ISRE-luciferase reporter. Therefore, this dual reporter system is allowing 
the quantification of both target cell lysis and interferon signaling from a single well, 
provided that experiments are performed at low E/T ratios. Finally, we tested Torin2, 
diphenhydramine, and dextromethorphan in this new assay. As expected, all three compounds 
were found to inhibit the lysis of target cells but interestingly (Fig. 6C, upper panel), only 
Torin2 completely blocked the expression of the ISRE-luciferase reporter (Fig. 6C, lower 
panel). The situation was intermediate with dextromethorphan, while the ISRE-luciferase 
 reporter was barely inhibited by diphenhydramine (Fig. 6C, lower panel). These profiles 
demonstrate the inhibitory properties of these drugs, but also support distinct modes of action 
for Torin2, dextrometorphan and diphenhydramine and different consequences on NK cell 
functions. Altogether, this validates our assay and highlights the interest of such a dual 
reporter system. 
 
Discussion  
 NK cells play a central role in the innate immune response against intracellular 
pathogens and tumor cells, are considered as prime targets for innovative immunotherapies, 
and functional defects are associated to pathological conditions. Both natural and artificial 
molecules, including cytokines, drugs and natural products, have been defined as modulators 
of NK cell activity, and some of them are developed for medical purposes. The identification 
of novel modulators requires both target-based approaches and functional screenings that are 
complementary. But the latter is complicated since current NK cell assays are not easily 
adapted to the high-throughput screening of large libraries of compounds. Besides, quick 
functional assays, ideally usable at the patient’s bedside, are needed for the quick diagnosis of 
pathological conditions such as FHL where NK cell cytotoxicity is altered.  
Luciferase-based functional assays have become increasingly popular because of the 
exceptional performances of this family of bioluminescent enzymes that emit a strong signal 
and are fully compatible with biological systems. Some attempts have been made to develop 
cell cytotoxicity assays based on firefly luciferase, but the poor stability of this enzyme after 
release in the extracellular medium greatly limited their performances15, 16, 31. This analytical 
issue was solved with the development of brighter, smaller and much more stable luciferases 
of marine origins such as NanoLuc that use coelenterazine or its chemical analog furimazine 
as a substrate17-19. As we were developing our system, two research groups recently 
 developed with success their own cytotoxicity assays by expressing these enzymes in target 
cells. They were used to measure Antibody-Dependent Cellular Cytotoxicity (ADCC), target 
cell lysis by Chimeric Antigen Receptor (CAR) expressing T cells, and complement-
dependent cytotoxicity32, 33. Performances were found to be at least similar to 51Cr release that 
is considered as the gold standard. Here, we established our own assay to measure the natural 
cytotoxicity of primary NK cells using appropriate targets, i.e. K562 or HEK293. Using 
PBMCs as a source of NK cells, this assay can be used to measure the inhibitory or 
stimulatory properties of small compounds or cytokines, but also to detect functional defects 
in PBMCs from patients (Fig. 4C). In the future, it will be interesting to further miniaturize 
this assay using 384-well plates as blood samples from patients, especially when testing 
babies, are limited in volume. Furthermore, we demonstrate the scalability of this assay as 
assessed by excellent statistical parameters. As proof of concept, we used the following 
settings to identify inhibitors of NK cells: 0.4.106 PBMCs/well at a 25/1 E/T ratio in a 96-well 
format. If we consider that 1.109 PBMCs are usually purified from one standard blood bag 
(500 ml), cells from a single donor are sufficient to screen 25 collection plates including 80 
compounds and control wells, which corresponds to 2,000 different molecules. This makes 
possible the screening of medium-scale libraries on primary effector cells, a key point when 
looking for relevant cytotoxicity modulators. 
 From the screen of the TMIC Human Metabolome Library, we identified 6 molecules 
that were previously described in literature for their inhibitory properties on NK cells24-29, and 
6 molecules that were not reported for this activity before. Interestingly, several of these 
molecules fall into pharmacological classes of drugs previously identified by Theorell & al.34 
as modulators of antibody-dependent NK cytotoxicity, including adrenergic receptor ligands 
(propranolol), Ca2+ channel blocker (verapamil, diltiazem), H1R-antagonist 
(diphenhydramine, brompheniramine), serotonergic, dopaminergic, and muscarinergic 
 antagonists (diphenhydramine, brompheniramine, dextrometorphan) ¾, and with sometimes 
opposite effects (17α-Ethynylestradiol). However, all these drugs have multiple side targets, 
and mechanisms responsible for their biological activity towards PBMCs, and NK cells in 
particular, remain elusive without further investigations. Among the new NK cell inhibitors 
identified in the screen, dextromethorphan and diphenhydramine were the most interesting, 
showing some potent effects with a limited cytotoxicity on PBMCs. Dextrometorphan (d-3-
methoxy-17-methylmorphinan) belongs to the morphinian family, and is widely prescribed as 
a cough suppressant but is also used in the treatment of specific neurological disorders. It 
shows no affinity for the opioid receptor, but was characterized as a nanomolar to low 
micromolar range antagonist of NMDA receptor, an agonist of the s1 receptor (σ1R), a 
serotonin–norepinephrine reuptake inhibitor, an antagonist of nicotinic receptors, and an 
inhibitor of voltage-gated calcium and potassium channels35. Interestingly, it was previously 
reported to have immunosuppressive properties at higher concentrations, for example 
inhibiting the maturation of conventional dendritic cells36, but also disease progression in 
experimental mouse models of autoimmune disorders37, 38, or inflammation and oxidative 
stress in heavy smokers39. Mechanisms involved are still poorly understood, but could also 
control the activation of NK cells. One hypothesis is that dextrometorphan, through 
interactions with σ1R or voltage-gated channels, perturbs Ca2+ mobilization that is essential 
for NK cell activation and degranulation. A second inhibitor of interest identified in the 
screen was diphenhydramine, a common first generation H1-antihistamine, which is closely 
related to brompheniramine that was also among selected hits. The IC50 of diphenhydramine 
for the H1 receptor is in the nM range, which is incompatible with the higher concentrations 
required for inhibiting NK cells (Fig. 5C). Diphenhydramine has pharmacological interactions 
with multiple secondary targets, including muscarinic and  a-adrenergic receptors, but also 
organic cation, serotonin, dopamine and norepinephrine transporters40. Several of these 
 receptors are expressed by immune cells, and are potentially involved the inhibitory effects of 
diphenhydramine on NK cells. This is supported by a report showing that diphenhydramine is 
suppressing the innate immune response in a mouse model of septic peritonitis, and these 
effects are not mediated by H1R41. Altogether, our data suggest that diphenhydramine, 
dextrometorphan, and related drugs that are widely used to treat the symptoms of common 
cold may have unwanted effects on the innate immune response. This adds elements to the 
current debate on the low benefit/risk ratio of these molecules. Finally, it should be noticed 
that we did not identify NK cell activators in the screen, probably because 
immunostimulatory molecules, that potentially induce inflammation, are relatively rare 
amongst prevalent metabolites or frequently used drug. 
 Finally, we further improved our screening system by developing an original dual-
reporter cell line to monitor both the secretion of IFN-g by NK cells and their cytotoxic 
activity. Results obtained showed a good correlation between NK cell cytotoxicity and IFN-g 
expression as expected (Fig. 6B). Interestingly, when testing NK cell inhibitors in this dual 
reporter system, we found that Torin2 efficiently blocked target cell lysis and the IFN 
response, whereas the effects of dextromethorphan and diphenhydramine were skewed for the 
inhibition of NK cell cytotoxicity (Fig. 6C). This suggests that these drugs have different 
modes of action. Cytotoxic granules with perforin/granzymes and vesicles containing IFN-g 
are separate entities, which are delivered to the surface of NK cells through different secretory 
pathways30. While the secretion of IFN-g vesicles is not polarized, cytotoxic granules are 
released at the contact interface with target cells and this pathway could be selectively 
inhibited, in particular by diphenhydramine. Further experiments using purified NK cells and 
cellular imaging should be performed to test this hypothesis. Finally, it should be stressed that 
the dual-reporter assay we developed should be performed at a relatively low E/T ratio to let 
the expression of IFN-g induce the ISRE-luc reporter before target cells are killed. Provided 
 that this rule is properly followed, this dual reporter system will provide much more complete 
functional data on the activation of NK cells when screening libraries of compounds or 
biologics in high-throughput settings. In the future, this should help identify modulators of 
NK cells of interest for developing innovative therapies.  
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 Figure Legends 
Figure 1: Principle of the luciferase-based cytotoxicity assay. PBMCs are co-cultured with 
target cells expressing high levels of NanoLuc in the intracellular compartment. After few 
hours of incubation, NK cells from PBMCs mediate the lysis of target cells, thus releasing 
NanoLuc in culture supernatant. NanoLuc activity in culture supernatant reflects target cell 
lysis. 
 
Figure 2: Nanoluc accumulates in culture supernatants of K562-NL cells when killed by 
chemical of physical treatments. (A) K562-NL cells were treated with 1% Tergitol, and 
NanoLuc released in culture supernatants was determined at different time-points. 
Alternatively, ATP in culture culture wells was quantified as a measure of cellular viability. 
Raw luminescence values were normalized to the signal obtained with living K562-NL cells 
alone. (B) K562-NL cells were dispensed at different concentrations in culture wells, and 
maintained alive or killed by freezing-and-thawing. When indicated, 400.000 PBMCs were 
added to culture wells containing dead K562-NL cells. Cell cultures were immediately 
centrifuged, and NanoLuc activity quantified in culture supernatants. Raw luminescence 
values were normalized to the signal obtained with 80.000 living K562-NL cells alone. All 
data correspond to means ± SD of three independent experiments. “ns” is for non-significant 
as determined by two-way ANOVA with Bonferroni post-hoc test. 
 
Figure 3: Measuring NK cell cytotoxicity with K562-NL target cells. (A) PBMCs were co-
cultured with K562-NL cells at different effector/target (E/T) ratios. NanoLuc activity in 
culture supernatants was measured after 4 h of incubation. Results were expressed as a 
percentage of NanoLuc released by K652-NL cells permeabilized with 1% Tergitol. In 
parallel experiments, the number of dead K562-NL cells in co-cultures was determined by 
 LIVE/DEAD viability staining and flow cytometry analysis. (B) PBMCs were co-cultured 
with K562-NL at a 25/1 ratio, and Nanoluc activity in culture supernatants was determined at 
different time-points. (C) PBMCs from 13 different donors were co-cultured with K562-NL at 
a 25/1 ratio, and Nanoluc activity in culture supernatants was determined after 4 h of co-
culture. Each circle corresponds to one specific donor, and the mean ± SD is represented (D) 
NK cells were co-cultured with K562-NL cells at different E/T ratios, and NanoLuc activity 
in culture supernatants was determined after 4 h of incubation. (E) Total PBMCs or PBMCs 
depleted of NK cells (w/oNK) were co-cultured with K562-NL cells at a 25/1 ratio, and 
NanoLuc activity in supernatants was determined after 4 h of incubation. The “w/oNK+NK” 
condition corresponds to PBMCs depleted of NK cells that were reconstituted with 8% of 
purified NK cells. (A-D) Results were expressed as a percentage of NanoLuc released by 
K562-NL cells permeabilized with 1% Tergitol. All data correspond to means ± SD of at least 
three donors. (*) p < 0.05, (**) p < 0.01 (***) p < 0.001 as determined by one-way ANOVA 
with Bonferroni post-hoc test. “ns” is for non-significant. 
 
Figure 4: Testing the effects of known modulators of NK cell cytotoxicity. (A) PBMCs were 
pretreated overnight with R848 (15 µM) to stimulate the cytotoxicity of NK cells. K562-NL 
target cells were added, and NanoLuc activity in culture supernatants was determined after 4 
h of co-culture. Data correspond to means ± SD of one representative experiment of three 
performed in triplicate. (B) PBMCs were pretreated overnight with IL-15 (100 ng/ml), TGF-
 b (10 ng/ml) or Torin2 (250 nM), and then K562-NL target cells were added. Experiment 
was performed at an E/T ratio of 30, and cells were co-cultured for 4 h at 37°C before 
NanoLuc activity was determined in culture supernatants. Data correspond to means ± SD of 
three donors. (C) The cytotoxicity of PBMCs from a perforin -/- patient was compared to a 
healthy donor. PBMCs were co-cultured with K562-NL at different E/T ratio and after 7 h at 
 37°C, NanoLuc activity in culture supernatants was determined. Results were expressed as a 
percentage of NanoLuc released by K562-NL cells when permeabilized with 1% Tergitol (A 
and C) or co-cultured with IL2-stimulated PBMCs at a 100:1 E/T ratio (B). Data correspond 
to means ± SD of one experiment performed in duplicate. (*) p < 0.05, (**) p < 0.01 (***) p < 
0.001 as determined by two-way ANOVA (A and C) or one-way ANOVA (B) with 
Bonferroni post-hoc test. “ns” is for non-significant. 
 
Figure 5: Screening a chemical library of metabolites, xenobiotics and common drugs. 
PBMCs from two healthy donors were used to screen the TMIC Human Metabolome Library. 
(A) Screening pipeline showing the selection of non-toxic inhibitors of NK cell cytotoxicity. 
The viability of PBMCs was determined by ATP quantification in culture wells. Measuring 
NanoLuc levels in culture supernatants assessed the inhibition of target cell lysis. (B) Twelve 
compounds were found to inhibit target cell lysis in two independent screens. pIC50s 
correspond to –log10 values of the IC50s as determined on PBMCs from ³3 healthy donors. 
References correspond to former studies already showing the inhibition of NK cells. (C) 
Dose-response experiments showing the viability of PBMCs and the inhibition of target cell 
lysis. (A-C) Results were expressed as a percentage of NanoLuc released by K562-NL cells 
when co-cultured with untreated PBMCs. Data correspond to means ± SD of ³3 healthy 
donors. 
 
Figure 6: Measuring NK cell cytotoxicity and IFN secretion with dual-reporter cells. (A) 
Recombinant human IFN-g is inducing the ISRE-Luciferase reporter gene in twINNE cells. 
Firefly luciferase activity was determined after 24 h of incubation. (B) PBMCs were co-
cultured with twINNE cells at different effector/target (E/T) ratios. NanoLuc activity in 
culture supernatants was measured after 7 h of incubation. Results were expressed as a 
 percentage of NanoLuc released by twINNE cells permeabilized with 1% Tergitol. In parallel, 
ISRE-Luc induction was determined in cell cultures at the same time point. (C) Same 
experiment as above at an E/T ratio of 4 with PBMCs pre-treated overnight with Torin2 (500 
nM), dextromethorphan (Dex.; 140 µM) or diphenhydramine (Diph.; 170 µM). Upper and 
lower panels correspond to NanoLuc activity in supernatants and ISRE-Luc induction in co-
cultures, respectively. (A-C) Data correspond to means ± SD of ³3 experiments performed in 
duplicate. (*) p < 0.05, (**) p < 0.01 (***) p < 0.001 as determined by one-way ANOVA 
with Bonferroni post-hoc test. “ns” is for non-significant. 
 
 






